iShares Genomics Immunology and Healthcare ETF
Price through Sep 30 · Flows through Sep 29. Figures use the latest available records, not a live quote. Fund details retrieved Oct 1. Holdings snapshot retrieved Oct 1.
The fund generally will invest at least 80% of its assets in the component securities of the index and in investments that have economic characteristics that are substantially identical to the component securities of the index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. The index is composed of developed and emerging market companies that could benefit from the long-term growth and innovation in genomics, immunology and bioengineering. It is non-diversified.
SOURCE: MARKET TAPE & DAILY CREATION/REDEMPTION RECORDS · 1Y SHOWN · NET +$75M OVER THIS RANGE
Money keeps arriving — +$20M of net inflows over the past month, about 6.7% of the fund's asset base, while the price has returned +59.0% so far this year. At 0.47% a year it is not the cheapest way in — FDHT has a reported fee of 0.39%.
COMPOSED FROM THE FUND’S OWN DAILY RECORDS · UPDATED WITH EACH REFRESH
CELL SIZE IS PORTFOLIO WEIGHT · COLOR IS THE CHANGE IN THE LATEST AVAILABLE SNAPSHOT · TOP 40 POSITIONS
| # | Holding | Weight | Price | Day | 52-wk | |
|---|---|---|---|---|---|---|
| 1 | MRNAMODERNA | 11.84% | $188.94 | -1.9% | ||
| 2 | TWSTTWIST BIOSCIENCE | 7.42% | $188.05 | -2.7% | ||
| 3 | GSKGSK | 2.61% | $47.18 | -2.1% | ||
| 4 | IOVAIOVANCE BIOTHERAPEUTICS | 4.86% | $14.23 | -4.0% | ||
| 5 | RVMDREVOLUTION MEDICINES | 3.78% | $205.89 | +0.3% | ||
| 6 | MRKMERCK & CO | 3.41% | $143.81 | -1.0% | ||
| 7 | REGNREGENERON PHARMACEUTICALS | 3.26% | $734.81 | -3.1% | ||
| 8 | INCYINCYTE | 3.32% | $117.14 | -3.5% | ||
| 9 | VRTXVERTEX PHARMACEUTICALS | 3.25% | $506.74 | -3.1% | ||
| 10 | EXELEXELIXIS | 3.07% | $57.94 | -0.8% | ||
| 11 | BNTXBIONTECH SE | 3.09% | $96.85 | -1.5% | ||
| 12 | IBRXIMMUNITYBIO | 2.88% | $9.28 | -1.7% | ||
| 13 | CAICaris Life Sciences | 3.35% | $28.35 | -7.4% | ||
| 14 | ABCLABCELLERA BIOLOGICS | 3.01% | $13.91 | -4.7% | ||
| 15 | IDYAIDEAYA BIOSCIENCES | 2.73% | $37.81 | -1.6% |
The full book, free with one sign-in.
Top 15 positions are open to everyone. Sign in once and every fund’s complete holdings — plus CSV export, watchlists, and flow alerts — unlock across the network.
Sign in to see all 63| 1 week | -0.3% |
| 1 month | +5.0% |
| 3 months | +23.9% |
| 6 months | +49.7% |
| YTD | +59.0% |
| 1 year | +71.1% |
| 3 years | — |
PRICE RETURN, DISTRIBUTIONS NOT REINVESTED
| 1 week | +$8M |
| 1 month | +$20M |
| 3 months | +$61M |
| YTD | +$75M |
| 1 year | +$75M |
CREATION/REDEMPTION DOLLARS, DAILY RECORDS
The top holding is 11.8% of the book; the top ten carry 49%. Spread across 52+ names, it behaves like roughly 24 equally-weighted positions.
VOLATILITY & DRAWDOWN FROM THE DAILY TAPE · CONCENTRATION FROM THE LATEST DISCLOSED BOOK
| Most-traded holdings, options premium | Bullish | Bearish |
|---|---|---|
| MRNA MODERNA | $35M | $34M |
| IOVA IOVANCE BIOTHERAPEUTICS | $3M | $4M |
| MRK MERCK & CO | $3M | $2M |
| REGN REGENERON PHARMACEUTICALS | $1M | $2M |
| JANX JANUX THERAPEUTICS | $1M | $1M |
TODAY’S OPTIONS PREMIUM IN THE FUND’S UNDERLYING NAMES
Due diligence cuts both ways. These funds sit on the same shelf and beat IDNA on at least one dimension that matters — the fee, the asset base, or where the money is going.
| Fund | Fee | Assets | Flow, 1M | The case | |
|---|---|---|---|---|---|
| SPDW State Street SPDR Portfolio Developed World ex-US ETF | 0.03% | $41.5B | +$286M | -44bp on fee · 139× the assets · +$286M in over the month | Head-to-head |
| SPMD State Street SPDR Portfolio S&P 400 Mid Cap ETF | 0.03% | $18.2B | +$199M | -44bp on fee · 61× the assets · +$199M in over the month | Head-to-head |
| IDEV iShares Core MSCI International Developed Markets ETF | 0.04% | $32.9B | +$497M | -43bp on fee · 110× the assets · +$497M in over the month | Head-to-head |
| IGSB iShares 1-5 Year Investment Grade Corporate Bond ETF | 0.04% | $23.7B | +$575M | -43bp on fee · 79× the assets · +$575M in over the month | Head-to-head |
| IGIB iShares 5-10 Year Investment Grade Corporate Bond ETF | 0.04% | $18.6B | +$412M | -43bp on fee · 62× the assets · +$412M in over the month | Head-to-head |